FaceYa FaceYa
Resultados de la búsqueda
Ver todos los resultados
  • Participar
    Iniciar sesión
    Registrarse
    Buscar
    Theme Switcher
    Night Mode

Buscar

Descubre nuevas personas, crear nuevas conexiones y hacer nuevos amigos

  • Noticias Feed
  • EXPLORE
  • Páginas
  • Grupos
  • Eventos
  • Blogs
  • Ofertas
  • Empleos
  • Courses
  • Foros
  • Películas
  • Juegos
  • Entradas
  • Blogs
  • Usuarios
  • Páginas
  • Grupos
  • Eventos
  • Wang Judy agregó una foto Other
    2026-05-14 06:29:15 -
    GC Biotech’s Role in High-Performance Immune Potentiating Adjuvant Development
    In vaccine development and immunotherapy, one of the most critical challenges is not only delivering an antigen, but ensuring the immune system responds to it in a strong, controlled, and durable way. In many cases, antigens alone are not sufficient to trigger an optimal immune response. This is where immune potentiating adjuvants play a central role. Immune potentiating adjuvants are...
    0 Commentarios 0 Acciones 666 Views 0 Vista previa
    Please log in to like, share and comment!
  • Wang Judy agregó una foto Other
    2026-05-28 08:09:27 -
    New Application Scenarios for the AS01 Adjuvant: The ACI-24.060 Alzheimer’s Disease Vaccine Project
    The treatment of Alzheimer’s Disease (AD) has entered the era of "Disease-Modifying Therapies" (DMTs). With the approval of anti-Aβ monoclonal antibodies (such as Lecanemab), the Amyloid Cascade Hypothesis has received clinical validation. However, the safety risks associated with ARIA (Amyloid-Related Imaging Abnormalities) in monoclonal antibody therapies, as well as their high...
    0 Commentarios 0 Acciones 292 Views 0 Vista previa
    Please log in to like, share and comment!
  • Wang Judy agregó una foto Other
    2026-06-10 06:59:58 -
    The Potential and Advantages of Using the AS01 Adjuvant in Next-Generation Adjuvanted Influenza Vaccines
    Influenza vaccines represent one of the largest segments of the global vaccine market (with the global market size exceeding $8 billion by 2025). However, the protective efficacy of traditional split-virus vaccines has long hovered between 30% and 50% among individuals aged 65 and older and immunocompromised populations. Additionally, these vaccines require annual updates, offer short-term...
    0 Commentarios 0 Acciones 6 Views 0 Vista previa
    Please log in to like, share and comment!
  • Wang Judy agregó una foto Other
    2026-04-10 02:57:04 -
    【Dual Exhibition Tour】GC Biotech's June Roadshow: Veterinary Adjuvant Innovation × Human Vaccine Breakthrough – Dual Tracks Driving the Future of Immunity
    This June, GC Biotech will participate in two major industry exhibitions in China, bringing together the latest innovations in veterinary drugs, vaccine adjuvants, and pharmaceutical technologies. These events provide an important platform for global collaboration, technological exchange, and industry advancement. We sincerely invite partners and industry professionals to visit us, explore new...
    0 Commentarios 0 Acciones 833 Views 0 Vista previa
    Please log in to like, share and comment!
© 2026 FaceYa Spanish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek 简体中文 日本語 한국어 繁体中文
About Términos Privacidad Contact Us Directorio